Vaccines are critical tools for maintaining global health. Traditional vaccine technologies
have been used across a wide range of bacterial and viral pathogens, yet there are a …

HIV infection can be effectively treated by lifelong administration of combination antiretroviral
therapy, but an effective vaccine will likely be required to end the HIV epidemic. Although the …

Background More than 1· 8 million new cases of HIV-1 infection were diagnosed worldwide
in 2016. No licensed prophylactic HIV-1 vaccine exists. A major limitation to date has been …

AZD1222 (ChAdOx1 nCoV-19), a replication-deficient simian adenovirus–vectored vaccine,
has demonstrated safety, efficacy, and immunogenicity against coronavirus disease 2019 in …

This review examines the enormous progress that has been made in the past decade in
understanding the origin of HIV, HIV genetic variability, and the impact of global HIV diversity …

Introduction The development of an effective vaccine to protect against HIV is a longstanding
global health need complicated by challenges inherent to HIV biology and to the execution …

The sequence of microbial genomes made all potential antigens of each pathogen available
for vaccine development. This increased by orders of magnitude potential vaccine targets in …

Adenoviral vectors are a safe and potently immunogenic vaccine delivery platform. Non-
replicating Ad vectors possess several attributes which make them attractive vaccines for …

The global diversity of HIV-1 represents a critical challenge facing HIV-1 vaccine
development. HIV-1 mosaic antigens are bioinformatically optimized immunogens designed …

Preclinical studies of human immunodeficiency virus type 1 (HIV-1) vaccine candidates have
typically shown post-infection virological control, but protection against acquisition of …